← Evidence map

ReviewDrugs2017

Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor.

Joleen M Hubbard et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

83 papers cite itlatest 60 shown

2017
…
2020
2021
2022
2023
2024
2025
2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 28573435